Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism

@article{Bhamidipati2005PreclinicalAO,
  title={Pre-clinical assessment of DRF 4367, a novel COX-2 inhibitor: Evaluation of pharmacokinetics, absolute oral bioavailability and metabolism in mice and comparative inter-species in vitro metabolism},
  author={R. Bhamidipati and S. Mujeeb and P. Dravid and A. A. Khan and S. Singh and Y. Rao and R. Mullangi and N. Srinivas},
  journal={Xenobiotica},
  year={2005},
  volume={35},
  pages={253 - 271}
}
  • R. Bhamidipati, S. Mujeeb, +5 authors N. Srinivas
  • Published 2005
  • Chemistry, Medicine
  • Xenobiotica
  • The aim of this study was to characterize the pharmacokinetics and determine the absolute bioavailability and metabolism of DRF 4367, a novel COX-2 inhibitor, in mice. In addition, the in vitro metabolism of DRF 4367 was studied in mouse, rat, dog, monkey and human liver microsomes. Following oral administration, maximum concentrations of DRF 4367 were achieved after about 1 h. Upon intravenous (IV) administration, the concentration of DRF 4367 declined in a bi-exponential fashion with a… CONTINUE READING
    8 Citations

    References

    SHOWING 1-10 OF 32 REFERENCES
    The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
    • 77
    • PDF
    Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice.
    • 33
    • PDF
    The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
    • 43
    • PDF
    Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
    • 76
    Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
    • 135
    • PDF
    Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects.
    • 71
    • PDF
    Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.
    • 50
    • PDF
    In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
    • 43
    • Highly Influential
    Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites.
    • 15
    • Highly Influential
    • PDF